Itamar Medical

Itamar Medical is a developer of home sleep tests (HSTs) and sleep apnea devices for patients and healthcare professionals.

History

2021: Zoll Medical bought Itamar Medical for $538 million

On September 13, 2021, Zoll Medical announced the acquisition of Itamar Medical for $538 million. Under the terms of the agreement, Zoll will buy all outstanding shares of the developer of devices for diagnosing breathing disorders in sleep at a price of $31 per US deposited share (ADS).

According to the press release, the boards of directors of both companies approved the transaction, it was approved by regulators and other conditions for closing the transaction, which is planned to be closed before the end of 2021, were met.

Zoll Medical acquired Itamar Medical for $538 million

Itamar is developing an FDA-certified home sleep apnea WatchPAT device designed to diagnose sleep in patients and healthcare professionals.

Zoll Medical aims to improve treatment outcomes for patients suffering from serious cardiopulmonary diseases. As of September 14, 2021, it is believed that 60% of patients with cardiovascular disease suffer from some form of sleep apnea and most of these patients remain undiagnosed. Combining Zoll Medical and Itamar Medical will help more patients get diagnosis and treatment of sleep breathing disorders. We look forward to strengthening the collaboration between cardiology and sleep medicine, "said Zoll CEO John Rennert.

Itamar CFO Shai Basson said in a release that the company believes that the transaction is in the best interests of various stakeholders. The integration of Itamar's WatchPAT technology and digital sleep apnea medical solution with Zoll Medical's commercial presence will accelerate the mission to advance home sleep medicine for the benefit of a population of undiagnosed and untreated patients.^[1]

Notes